|
Delayed
Bombay S.E.
09:18:16 21/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 4,532.40 INR | -0.39% |
|
-1.34% | +17.98% |
| 10-08 | India Ratings Revises Torrent Pharma's Credit Outlook to Positive | MT |
| 09-28 | Torrent Pharma to Pay More for its 26% Stake in Power Unit After Amending Agreement | MT |
| Market Cap | 1,731B 18.27B 16.26B 15.07B 13.66B 25.67B 26.1B 181B 71.05B 906B 68.53B 67.11B 2,889B | P/E 2027 * |
67.2x | P/E 2028 * | 48.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1,853B 19.56B 17.41B 16.13B 14.62B 27.47B 27.93B 194B 76.05B 970B 73.36B 71.84B 3,093B | EV / Sales 2027 * |
9.35x | EV / Sales 2028 * | 8.17x |
| Free-Float |
36.82% | Yield 2027 * |
0.72% | Yield 2028 * | 0.84% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| TORNTPHARM | Delayed | |
NSE India S.E.
| TORNTPHARM | Delayed |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -0.39% | ||
| 1 week | -1.34% | ||
| Current month | -5.60% | ||
| 1 month | -8.77% | ||
| 3 months | -10.05% | ||
| 6 months | +9.64% | ||
| Current year | +17.98% |
| 1 week | 4,525 |  | 4,656.85 |
| 1 month | 4,525 | | 5,010 |
| Current year | 3,724.1 | | 5,249.95 |
| 1 year | 3,532.85 | | 5,249.95 |
| 3 years | 1,822.8 | | 5,249.95 |
| 5 years | 1,242.5 | | 5,249.95 |
| 10 years | 571.75 | | 5,249.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 01/08/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 01/09/2018 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 30/07/2014 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 07/03/2019 |
| Director/Board Member | 59 | 29/07/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/11/24 | Buy | Chief Operating Officer | 930,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -1.34% | +26.25% | +141.83% | 18.27B | |
| +3.49% | +10.04% | +58.68% | +119.56% | 1,144B | |
| +2.19% | +4.32% | +33.88% | +69.52% | 625B | |
| +2.26% | +5.37% | +24.57% | +97.69% | 511B | |
| +2.58% | +8.37% | +38.71% | +63.14% | 377B | |
| +3.25% | +4.45% | +71.80% | +44.44% | 366B | |
| +1.85% | +6.04% | +21.47% | +49.17% | 291B | |
| +1.76% | +6.07% | +0.43% | +20.98% | 262B | |
| +3.29% | +6.32% | +44.71% | +57.43% | 237B | |
| +2.25% | +5.81% | +27.13% | +101.17% | 194B | |
| Average | +1.80% | +3.50% | +34.76% | +76.49% | 402.62B | |
| Weighted average by Cap. | +1.42% | +4.65% | +40.85% | +80.95% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 198B 2.09B 1.86B 1.73B 1.56B 2.94B 2.99B 20.71B 8.14B 104B 7.85B 7.69B 331B | 223B 2.36B 2.1B 1.94B 1.76B 3.31B 3.37B 23.33B 9.16B 117B 8.84B 8.66B 373B |
| Net income | 24.66B 260M 232M 215M 195M 366M 372M 2.58B 1.01B 12.9B 976M 956M 41.16B | 34.21B 361M 321M 298M 270M 507M 516M 3.57B 1.4B 17.9B 1.35B 1.33B 57.11B |
| Net Debt | 122B 1.29B 1.14B 1.06B 962M 1.81B 1.84B 12.73B 5B 63.77B 4.83B 4.73B 203B | 93.13B 983M 875M 811M 735M 1.38B 1.4B 9.73B 3.82B 48.74B 3.69B 3.61B 155B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/10/26 | ₹4,532.40 | -0.39% | 2,437 |
| 19/10/26 | ₹4,550.30 | -0.21% | 4,437 |
| 16/10/26 | ₹4,560.00 | -1.00% | 2,898 |
| 15/10/26 | ₹4,605.95 | +0.26% | 5,893 |
| 14/10/26 | ₹4,594.00 | -0.88% | 104,340 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
